Fibrosing colonopathy
| Fibrosing colonopathy | |
|---|---|
| Other names | Abdominal pain, abdominal swelling, vomiting, constipation[1] |
| Causes | High doses of pancreatic enzyme supplements[1] |
| Risk factors | Young age, prior surgery of the intestines, certain medications including corticosteroids and H2 blockers[2] |
| Frequency | >60 cases reported[2] |
Fibrosing colonopathy is a disease that arises in people with cystic fibrosis treated with high doses of pancreatic enzyme supplements.[1][2] Symptoms are non-specific with abdominal pain, abdominal swelling, vomiting, and constipation.[1]
Risk factors include being young, prior surgery of the intestines, and the use of certain medications including corticosteroids and H2 blockers.[2] It may appear similar to distal intestinal obstruction syndrome or inflammatory colitis such as Crohn's disease.[1]
A maximum dose of 10,000 IU of lipase per kilogram per day is recommended for pancreatic enzyme supplementation to prevent this condition.[3] More than 60 cases have been described as of 1999.[2] The disease was suggested to be caused by methacrylic acid copolymer which is used as coating for delayed release of enzymes but there is no reliable evidence for that.[4]
References
- ^ a b c d e Smyth RL (May 1996). "Fibrosing colonopathy in cystic fibrosis". Archives of Disease in Childhood. 74 (5): 464–8. doi:10.1136/adc.74.5.464. PMC 1511547. PMID 8669970.
- ^ a b c d e Lloyd-Still, JD; Beno, DW; Kimura, RM (June 1999). "Cystic fibrosis colonopathy". Current Gastroenterology Reports. 1 (3): 231–7. doi:10.1007/s11894-999-0040-4. PMID 10980955. S2CID 37595322.
- ^ Schibli, S; Durie, PR; Tullis, ED (November 2002). "Proper usage of pancreatic enzymes". Current Opinion in Pulmonary Medicine. 8 (6): 542–6. doi:10.1097/00063198-200211000-00010. PMID 12394164.
- ^ Borum, M. L.; Ginsberg, A. L. (1999). "Lack of evidence for fibrosing colonopathy by 5-ASA in humans". Digestive Diseases and Sciences. 44 (7): 1494. doi:10.1023/a:1026676407838. PMID 10489937. S2CID 34629882.